Trial Profile

A Four-week, Double-blind, Placebo-controlled, Randomized, Multicenter, Parallel-group Study of the Safety and Efficacy of NLS-2 (Mazindol Extended Release) in Adults for the Treatment of Narcolepsy

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 03 Jan 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Mazindol (Primary)
Indications Hypersomnia; Narcolepsy
Focus Therapeutic Use
Sponsors NLS Pharmaceutics Ltd

Most Recent Events

29 Dec 2023 According to NLS Pharmaceutics Ltd media release, data from this study presented at Sleep Research Society (SRS).
29 Dec 2023 Primary endpoint (Change in ESS Score From Baseline to Week 4) has been met as per results published in the NLS Pharmaceutics Ltd Media Release
29 Dec 2023 Results published in the NLS Pharmaceutics Ltd Media Release

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com